U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06811558) titled 'Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis' on Nov. 18, 2024.
Brief Summary: Currently, the main systemic drug therapies in China include methotrexate (MTX), cyclosporine A, retinoids, and biologics. In recent years, monoclonal antibody biologics targeting cellular inflammatory factors have been used in the treatment of severe psoriasis, which is poorly treated with conventional systemic medications, severely affects the quality of life, and is accompanied by significant arthritic symptoms, including tumor necrosis factor-alpha (TNF-alpha) antagonists (etanercept, infliximab, adalimumab); IL-12/23 antag...